Table 2 Pipeline containing (pre) clinical studies on monoclonal antibodies targeting infectious diseases
Disease | Preclinical* | Phase 1 | Phase 2 | Phase 3 | Phase 4 |
|---|---|---|---|---|---|
Diarrheal disease | |||||
 non-typhoid Salmonella spp. | 4 | no studies | no studies | no studies | no studies |
 Shigella spp | 1 | no studies | no studies | no studies | no studies |
 Yersinia enterocolitica | no studies | no studies | no studies | no studies | no studies |
 Campylobacter jejuni | 1 | no studies | no studies | no studies | no studies |
 Vibrio cholerae | 2 | no studies | no studies | no studies | no studies |
 Enterotoxigenic E. coli | 4 | no studies | no studies | no studies | no studies |
 Entamoeba histolytica | no studies | no studies | no studies | no studies | no studies |
 Cryptosporidium spp. | 1 | no studies | no studies | no studies | no studies |
 Giardia lamblia | no studies | no studies | no studies | no studies | no studies |
 Cyclospora | no studies | no studies | no studies | no studies | no studies |
Viral syndromes | |||||
 Dengue | 15 | AV-1 | no studies | no studies | no studies |
| Â | DenguShield | Â | Â | Â | |
 Zika | 17 | Tyzivumab | no studies | no studies | no studies |
| Â | DMAb-ZK190 | Â | Â | Â | |
 Chikungunya | 23 | mRNA-1944 | no studies | no studies | no studies |
| Â | SAR440894 | Â | Â | Â | |
 Japanese encephalitis | 2 | no studies | ImmunoRel | no studies | no studies |
 West Nile Virus | 4 | MGAWN1 | MGAWN1 | no studies | no studies |
 Tick-borne encephalitis | 3 | no studies | no studies | no studies | no studies |
 Rift Valley fever | 4 | no studies | no studies | no studies | no studies |
 Yellow fever | 5 | TY014 | no studies | no studies | no studies |
 Ebola Virus Disease | 47 | mAb114 (Ansuvimab) | Ansuvimab | Ansuvimab | Ansuvimab |
|  | REGN3470-3471–3479 (REGN-EB3) | REGN-EB3 | REGN-EB3 | REGN-EB3 | |
|  | Ebola (03-AT-2017) (GamEMab) | Gamezumab (01-AT-2020) | Gamezumab |  | |
| Â | Â | Zmapp | Zmapp | Â | |
 Lassa | 3 | no studies | no studies | no studies | no studies |
 Marburg | 9 | no studies | no studies | no studies | no studies |
 Crimean Congo HF | 3 | no studies | no studies | no studies | no studies |
 Hanta virus | 6 | no studies | no studies | no studies | no studies |
 Hepatitis A | no studies | no studies | no studies | no studies | no studies |
 Hepatitis B | 10 | Lenvervimab | Envafolimab | no studies | no studies |
| Â | HH-006 | FG-3019 | Â | Â | |
| Â | HH-003 | Cetrelimab | Â | Â | |
| Â | HepB mAb19 | HLX-10 | Â | Â | |
| Â | IMC-I109V | HH-003 | Â | Â | |
| Â | HepeX-B | Â | Â | Â | |
 Hepatitis C | 14 | Bavituximab | anti-CD3 | no studies | Tremelimumab |
| Â | MD11X06-02 | MBL-HCV1 | Â | Â | |
| Â | XTL6865 | CT-011 | Â | Â | |
| Â | CT-011 | Anti-IL2R | Â | Â | |
 Hepatitis E | 1 | no studies | no studies | no studies | no studies |
 Mpox | 4 | no studies | no studies | no studies | no studies |
Malaria | |||||
 Plasmodium spp. | 14 | CIS43LS | CIS43LS | no studies | no studies |
| Â | L9LS | L9LS | Â | Â | |
| Â | TB31F | Â | Â | Â | |
| Â | MAM01 | Â | Â | Â | |
| Â | Meplazumab | Â | Â | Â | |
Rabies | |||||
 Rabies virus | 8 | CL184 | CL184 | SII RMAb | SII RMAb |
| Â | SII RMAb | SII RMAb | SYN023 | Â | |
| Â | SYN023 | SYN023 | GR1801 | Â | |
| Â | Rabies mAb CBB1 | Docaravimab/ miromaviab | Docaravimab/ miromavimab | Â | |
| Â | Â | Ormutivimab | Ormutivimab | Â | |
Trypanosomiasis | |||||
 Trypanosomia cruzi | 5 | no studies | no studies | no studies | no studies |
Schistosomiasis | |||||
 Schistosoma spp. | 1 | no studies | no studies | no studies | no studies |
Tuberculosis | |||||
 Mycobacterium tuberculosa | 3 | no studies | Pascolizumab | no studies | no studies |
Other | |||||
 Leptospirosis | 1 | no studies | no studies | no studies | no studies |
 Typhoid fever | 1 | no studies | no studies | no studies | no studies |
 Melioidosis | 1 | no studies | no studies | no studies | no studies |
 Rickettsioses | no studies | no studies | no studies | no studies | no studies |
 Strongyloidiasis | no studies | no studies | no studies | no studies | no studies |
 Leishmaniasis | 6 | SCH708980 | SCH708980 | no studies | no studies |